Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

97 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Refractory and 17p-deleted chronic lymphocytic leukemia: improving survival with pathway inhibitors and allogeneic stem cell transplantation.
Farina L, Barretta F, Scarfò L, Bruno B, Patriarca F, Frustaci AM, Coscia M, Salvetti C, Quaresmini G, Fanin R, Onida F, Magagnoli M, Zallio F, Vallisa D, Reda G, Ferrario A, Corradini P, Montillo M. Farina L, et al. Among authors: magagnoli m. Biol Blood Marrow Transplant. 2020 Oct;26(10):e256-e262. doi: 10.1016/j.bbmt.2020.06.032. Epub 2020 Jul 9. Biol Blood Marrow Transplant. 2020. PMID: 32653626 Free article.
Reduced intensity conditioning regimen followed by glycosylated G-CSF mobilized PBSCT in patients with solid tumors and malignant lymphomas.
Castagna L, Bertuzzi A, Nozza A, Siracusano L, Balzarotti M, Magagnoli M, Sarina B, Timofeeva I, Sinnone M, Grimoldi MG, Farè M, Santoro A. Castagna L, et al. Among authors: magagnoli m. Bone Marrow Transplant. 2002 Aug;30(4):207-14. doi: 10.1038/sj.bmt.1703626. Bone Marrow Transplant. 2002. PMID: 12203136 Clinical Trial.
Allogeneic stem cell transplantation compared with chemotherapy for poor-risk Hodgkin lymphoma.
Castagna L, Sarina B, Todisco E, Magagnoli M, Balzarotti M, Bramanti S, Mazza R, Anastasia A, Bacigalupo A, Aversa F, Soligo D, Giordano L, Santoro A. Castagna L, et al. Among authors: magagnoli m. Biol Blood Marrow Transplant. 2009 Apr;15(4):432-8. doi: 10.1016/j.bbmt.2008.12.506. Epub 2009 Feb 12. Biol Blood Marrow Transplant. 2009. PMID: 19285630 Free article.
High-dose melphalan with autologous stem cell support in refractory Hodgkin lymphoma patients as a bridge to second transplant.
Castagna L, Crocchiolo R, Giordano L, Bramanti S, Carlo-Stella C, Sarina B, Chiti A, Mauro E, Gandolfi S, Todisco E, Balzarotti M, Anastasia A, Magagnoli M, Brusamolino E, Santoro A. Castagna L, et al. Among authors: magagnoli m. Bone Marrow Transplant. 2015 Apr;50(4):499-504. doi: 10.1038/bmt.2014.304. Epub 2015 Jan 26. Bone Marrow Transplant. 2015. PMID: 25621797
B-IGEV (bortezomib plus IGEV) versus IGEV before high-dose chemotherapy followed by autologous stem cell transplantation in relapsed or refractory Hodgkin lymphoma: a randomized, phase II trial of the Fondazione Italiana Linfomi (FIL).
Balzarotti M, Brusamolino E, Angelucci E, Carella AM, Vitolo U, Russo E, Congiu A, Gotti M, Massidda S, Botto B, Annechini G, Spina M, Re A, Zilioli VR, Merli F, Salvi F, Stelitano C, Bonfichi M, Rodari M, Murru R, Magagnoli M, Anastasia A, Mazza R, Giordano L, Santoro A. Balzarotti M, et al. Among authors: magagnoli m. Leuk Lymphoma. 2016 Oct;57(10):2375-81. doi: 10.3109/10428194.2016.1140161. Epub 2016 Feb 15. Leuk Lymphoma. 2016. PMID: 26879066 Clinical Trial.
A First-in-human Study of Tenalisib (RP6530), a Dual PI3K δ/γ Inhibitor, in Patients With Relapsed/Refractory Hematologic Malignancies: Results From the European Study.
Carlo-Stella C, Delarue R, Scarfo L, Barde PJ, Nair A, Locatelli SL, Morello L, Magagnoli M, Vakkalanka S, Viswanadha S, Ferreri AJM. Carlo-Stella C, et al. Among authors: magagnoli m. Clin Lymphoma Myeloma Leuk. 2020 Feb;20(2):78-86. doi: 10.1016/j.clml.2019.10.013. Epub 2019 Oct 23. Clin Lymphoma Myeloma Leuk. 2020. PMID: 31761713 Clinical Trial.
A phase Ib, open-label, dose-escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with gemcitabine and oxaliplatin in patients with relapsed/refractory diffuse large B-cell lymphoma.
Balzarotti M, Magagnoli M, Canales MÁ, Corradini P, Grande C, Sancho JM, Zaja F, Quinson AM, Belsack V, Maier D, Carlo-Stella C. Balzarotti M, et al. Among authors: magagnoli m. Invest New Drugs. 2021 Aug;39(4):1028-1035. doi: 10.1007/s10637-020-01054-6. Epub 2021 Feb 1. Invest New Drugs. 2021. PMID: 33523334 Free PMC article. Clinical Trial.
Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma.
Merryman RW, Castagna L, Giordano L, Ho VT, Corradini P, Guidetti A, Casadei B, Bond DA, Jaglowski S, Spinner MA, Arai S, Lowsky R, Shah GL, Perales MA, De Colella JMS, Blaise D, Herrera AF, Shouse G, Spilleboudt C, Ansell SM, Nieto Y, Badar T, Hamadani M, Feldman TA, Dahncke L, Singh AK, McGuirk JP, Nishihori T, Chavez J, Serritella AV, Kline J, Mohty M, Dulery R, Stamatoulas A, Houot R, Manson G, Moles-Moreau MP, Orvain C, Bouabdallah K, Modi D, Ramchandren R, Lekakis L, Beitinjaneh A, Frigault MJ, Chen YB, Lynch RC, Smith SD, Rao U, Byrne M, Romancik JT, Cohen JB, Nathan S, Phillips T, Joyce RM, Rahimian M, Bashey A, Ballard HJ, Svoboda J, Torri V, Sollini M, De Philippis C, Magagnoli M, Santoro A, Armand P, Zinzani PL, Carlo-Stella C. Merryman RW, et al. Among authors: magagnoli m. Leukemia. 2021 Sep;35(9):2672-2683. doi: 10.1038/s41375-021-01193-6. Epub 2021 Mar 3. Leukemia. 2021. PMID: 33658659
Chemotherapy after PD-1 inhibitors in relapsed/refractory Hodgkin lymphoma: Outcomes and clonal evolution dynamics.
Calabretta E, Guidetti A, Ricci F, Di Trani M, Monfrini C, Magagnoli M, Bramanti S, Maspero D, Morello L, Merli M, Di Rocco A, Graudenzi A, Derenzini E, Antoniotti M, Rossi D, Corradini P, Santoro A, Carlo-Stella C. Calabretta E, et al. Among authors: magagnoli m. Br J Haematol. 2022 Jul;198(1):82-92. doi: 10.1111/bjh.18183. Epub 2022 Apr 25. Br J Haematol. 2022. PMID: 35468225 Free PMC article.
97 results